How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Single-Cell Genomics Services Market
- By Technology: Single-Cell RNA Sequencing (scRNA-seq), Single-Cell DNA Sequencing (scDNA-seq), Single-Cell Epigenomics, Single-Cell Proteomics, Single-Cell Multiomics
- By Application: Oncology Research, Immunology Research, Neuroscience Research, Stem Cell Research, Drug Discovery and Development
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Clinical Research Organizations, Hospitals and Diagnostic Centers
- By Service Type: Sample Preparation and Isolation, Library Preparation and Sequencing, Data Analysis and Interpretation, Custom Assay Development, Consulting and Training Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Single-Cell RNA Sequencing (scRNA-seq) leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 11 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Single-Cell Genomics Services Market report
A complete, evidence-based study - 11 chapters and 114 sections covering market size, segmentation across 4 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Technology 5
Application 5
End User 5
Service Type 5
Companies profiled
10x Genomics
Illumina Inc.
BD Biosciences
Fluidigm Corporation
Mission Bio Inc.
Parse Biosciences
Dolomite Bio
Takara Bio Inc.
Bio-Rad Laboratories Inc.
Celsee Inc.
Singleron Biotechnologies
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →10x Genomics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BD Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fluidigm Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mission Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Parse Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Dolomite Bio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Takara Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bio-Rad Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Celsee Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Singleron Biotechnologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,459M by 2033 · 3.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Single-Cell RNA Sequencing (scRNA-seq)52.4
- Single-Cell DNA Sequencing (scDNA-seq)14.4
- Single-Cell Epigenomics13.1
- Single-Cell Proteomics13.2
- Single-Cell Multiomics6.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,083M → $1,551M · 4.6%
Europe$754.8M → $1,074M · 4.5%
Asia Pacific$689.2M → $988.9M · 4.6%
Latin America$426.6M → $581.2M · 3.9%
Middle East and Africa$328.2M → $501.1M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.862026
3.862027
3.882028
3.902029
3.912030
3.922031
3.932032
3.942033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- 10x Genomics8.5
- Illumina Inc.25.6
- BD Biosciences7.2
- Fluidigm Corporation10.6
- Mission Bio Inc.10.5
- Parse Biosciences9.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology18.9%
Application18.6%
End User33.1%
Service Type29.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe22.9
- Asia Pacific21.1
- Latin America12.4
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| 10x Genomics | 96 | 93 | 81 | 78 | 85 | 85 | 86 |
| Illumina Inc. | 90 | 68 | 74 | 90 | 79 | 76 | 80 |
| BD Biosciences | 84 | 81 | 78 | 72 | 73 | 84 | 79 |
| Fluidigm Corporation | 72 | 77 | 67 | 80 | 82 | 66 | 74 |
| Mission Bio Inc. | 65 | 60 | 66 | 64 | 72 | 75 | 67 |
| Parse Biosciences | 51 | 53 | 69 | 64 | 69 | 65 | 62 |
| Dolomite Bio | 60 | 66 | 51 | 51 | 63 | 52 | 57 |
| Takara Bio Inc. | 56 | 55 | 54 | 43 | 40 | 47 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- 10x Genomics
- Illumina Inc.
- BD Biosciences
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| 10x Genomics | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Illumina Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| BD Biosciences | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Fluidigm Corporation | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Mission Bio Inc. | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Parse Biosciences | ◐ | − | ◐ | − | ◐ | ◐ |
| Dolomite Bio | − | − | ◐ | − | − | ◐ |
| Takara Bio Inc. | ◐ | ◐ | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →110x Genomics86
2Illumina Inc.80
3BD Biosciences79
4Fluidigm Corporation74
5Mission Bio Inc.67
6Parse Biosciences62
7Dolomite Bio57
8Takara Bio Inc.49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
10x GenomicsIllumina Inc.BD Biosciences
Challenger2
Strong scale, closing on the leaders.
Fluidigm CorporationMission Bio Inc.
Contender2
Focused players with pockets of strength.
Parse BiosciencesDolomite Bio
Niche1
Specialists in a single segment or region.
Takara Bio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology in North America, then scale across Single-Cell Genomics Services Market — a $278M beachhead inside a $5.01B market.
Beachhead (SOM)$278Mobtainable near-term
Serviceable (SAM)$1.82Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Single-Cell RNA Sequencing (scRNA-seq)
Best fit — highest urgency & budget in Technology.
Economic buyer79 fit
Single-Cell DNA Sequencing (scDNA-seq)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Single-Cell Epigenomics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Single-Cell Genomics Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified22%
Evaluation11%
Closed-won8%
$11.5KCAC
$64KLTV
5.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Single-Cell Genomics Services Market is a durable-growth opportunity — $1.67B by 2033, compounding at 6.2%.
TAM · 2025$1.03Btoday
TAM · 2033$1.67Bforecast
CAGR6.2%2027–2033
Cumulative$11.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.67BTotal addressable market
SAM$700MServiceable available market
SOM$122MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.2% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.67BLarge & growingTAM by 2033 at 6.2% CAGR
$700MServiceable nowreachable with today’s model
$122MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.30BBear4.0% CAGR
$1.67BBase6.2% CAGR
$2.14BBull8.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Single-Cell Genomics Services Market — a $1.59B market by 2033. Plan: grow share from 9.1% to 14.2%.
Market size · 2033$1.59Btotal addressable
Market CAGR8.1%2027–2033
Target share14.2%from 9.1% today
Revenue ambition$226Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.2% | Behind |
| Revenue | $139M | $226M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.3% | 42.5% | At risk |
| Customer retention | 84.3% | 94.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $33M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Single-Cell Genomics Services Market conversation — a $6.55B market you can size, segment and defend in minutes.
Market size · 2033$6.55Btotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers1,267+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 4 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
10x GenomicsIllumina Inc.BD BiosciencesFluidigm CorporationMission Bio Inc.Parse BiosciencesDolomite BioTakara Bio Inc.+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Single-Cell Genomics Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Single-Cell Genomics Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Single-Chip Digital Imaging Radar Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportSingle-chip Microcomputer Experimental System Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportSingle-Column Matrix Scaffold Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportSingle-Crystal Diamond Film Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportSingle-Crystal Pulling Furnace Hot Zone Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportSingle-Cylinder Diesel Engine for Off-Road Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportSingle-Cylinder Diesel Engines Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportSingle-Dealer Platform Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSingle-Edge Notched Bend (SENB) Testers Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportSingle-engine Helicopter Market
Market size, share, segmentation and regional forecast.
$892M market · 2025 base year
View reportSingle-Ether Dianhydride (Odpa) Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportSingle-Family Residential Builder Hardware Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.